Novo Nordisk A/S and Anthropic PBC will work together to speed up drug development using artificial intelligence, a key goal as Novo tries to catch up in the cutthroat obesity market.
Novo Nordisk and Anthropic announced a collaboration to deploy Claude Science and other frontier AI models to speed up drug discovery and strengthen AI-driven software development, with initial testing on specific R&D workflows and a focus on robust data governance and human oversight.
Danish pharmaceutical company Novo Nordisk is partnering with American artificial intelligence company Anthropic, aiming to use Anthropic’s Claude model to advance its drug discovery research and development.
